{"disease":{"id":"malignant-solid-tumors","name":"malignant solid tumors"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03739827","title":"Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05594147","title":"An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib","phase":"","overall_status":"COMPLETED","enrollment_count":4103,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06702566","title":"The Effect of Serum Ferritin in irAE","phase":"NA","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT07307053","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT07480733","title":"Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":480,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT07287995","title":"A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":428,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT06115642","title":"A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":340,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":false},{"nct_id":"NCT04225117","title":"A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":329,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT06464055","title":"A Study of GQ1010 in Subjects With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"GeneQuantum Healthcare (Suzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT07292402","title":"JSKN022 in Subjects With Advanced Malignant Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":225,"lead_sponsor_name":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT02091999","title":"A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":213,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT02709889","title":"Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":200,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT07436728","title":"A Study of TAK-505 in Adults With Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":151,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT06154343","title":"A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"GeneQuantum Healthcare (Suzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT07124195","title":"Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":126,"lead_sponsor_name":"The First Affiliated Hospital of Xinxiang Medical College","has_results":false},{"nct_id":"NCT05538130","title":"A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":124,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05277454","title":"Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":113,"lead_sponsor_name":"Hutchison Medipharma Limited","has_results":false},{"nct_id":"NCT07368127","title":"A Study of TPD3310 in Patients With Advanced Malignant Tumors","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":112,"lead_sponsor_name":"TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD.","has_results":false},{"nct_id":"NCT06717750","title":"A Study of CSCJC3456 in Patients With Advanced Malignant Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":102,"lead_sponsor_name":"Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.","has_results":false},{"nct_id":"NCT06209580","title":"AMT-253 in Patients With Advanced Solid Tumours","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Multitude Therapeutics Inc.","has_results":false},{"nct_id":"NCT04328506","title":"Bioequivalency Study of CM082 Tablet in Healthy Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"AnewPharma","has_results":false},{"nct_id":"NCT06571422","title":"Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":93,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT05886374","title":"A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":81,"lead_sponsor_name":"Hutchmed","has_results":false},{"nct_id":"NCT06781125","title":"One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":72,"lead_sponsor_name":"Immorna Biotherapeutics, Inc.","has_results":false},{"nct_id":"NCT04226066","title":"Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":69,"lead_sponsor_name":"Tasly Tianjin Biopharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT01765790","title":"Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT05228015","title":"Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":67,"lead_sponsor_name":"Ikena Oncology","has_results":false},{"nct_id":"NCT07028047","title":"Evaluation of WGc-043 Injection in Advanced Solid Tumors: Phase I Study","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":64,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03205176","title":"AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04660929","title":"CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Carisma Therapeutics Inc","has_results":false},{"nct_id":"NCT00936364","title":"Short-Term Fasting: Impact on Toxicity","phase":"NA","overall_status":"TERMINATED","enrollment_count":47,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT04908046","title":"A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Hutchmed","has_results":false},{"nct_id":"NCT06573294","title":"Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Genmab","has_results":false},{"nct_id":"NCT06629584","title":"Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05773937","title":"A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Mabwell (Shanghai) Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT01519817","title":"Cancer Vaccine Targeting Brachyury Protein in Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06499350","title":"A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":33,"lead_sponsor_name":"FindCure Biosciences (ZhongShan) Co., Ltd.","has_results":false},{"nct_id":"NCT07444918","title":"Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":33,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT04168320","title":"SBRT-based PArtial Tumor Irradiation of HYpoxic Segment","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":30,"lead_sponsor_name":"Klinikum Klagenfurt am Wörthersee","has_results":false},{"nct_id":"NCT06658951","title":"Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"UTC Therapeutics Inc.","has_results":false},{"nct_id":"NCT02045095","title":"A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":29,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05326035","title":"A Study of WJ05129 in Advanced Malignant Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":26,"lead_sponsor_name":"Suzhou Junjing BioSciences Co., Ltd.","has_results":false},{"nct_id":"NCT02902237","title":"tTF-NGR Phase I Study","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"University Hospital Muenster","has_results":true},{"nct_id":"NCT07010523","title":"Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors","phase":"NA","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT05579275","title":"Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT04126668","title":"A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"AnewPharma","has_results":false},{"nct_id":"NCT06231550","title":"A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"FindCure Biosciences (ZhongShan) Co., Ltd.","has_results":false},{"nct_id":"NCT05749627","title":"Using Neoantigen Peptide Vaccine/neoantigen-based DC to Treat Advanced Malignant Solid Tumors","phase":"NA","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"The First Affiliated Hospital of Nanchang University","has_results":false},{"nct_id":"NCT05949775","title":"Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors","phase":"NA","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Stemirna Therapeutics","has_results":false},{"nct_id":"NCT06501183","title":"Anti-CDH17 CAR-T Cell Injection in Patients With CDH17-positive Advanced Malignant Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":17,"lead_sponsor_name":"Shanghai Pudong Hospital","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}